Leica Microsystems acquires Genetix to strengthen life science
imaging portfolio
25 March 2010
Leica Microsystems has acquired UK company Genetix Ltd, a
provider of systems for imaging and image analysis for clinical
research.
This acquisition brings together Genetix’ expertise in developing
and marketing imaging systems and software for clinical and research
applications, with Leica Microsystems’ microscopes and other life
science instrumentation.
The merger will enable both companies to fully realize their
potential through the combination of their ideally complemented
skill sets.
Genetix will exist as a separate business unit within Leica
Microsystems and Genetix products will continue to be marketed and
sold through existing channels. Customer services such as product
ordering, applications support and instrument service for Genetix
products will remain unchanged.
Charles de Rohan, Head of Genetix Business Unit within Leica
Microsystems, said: “Joining together with Leica Microsystems gives
Genetix greater access to global markets and increased financial
resources to achieve its growth plans. Over the past decade Genetix
has been building its presence in the life sciences, diagnostics and
digital pathology segments through a combination of internal product
development and acquisitions.
"Combining our strengthening presence with Leica Microsystems’
R&D capabilities, greater resources and global reach is in the best
interests of our shareholders, customers and employees and will
maximize the potential of our innovative technology. I would like to
take this opportunity to thank all our customers for their continued
support."
Stefan Traeger, Managing Director Life Science Division, Leica
Microsystems, said: "Genetix’ extensive expertise will be invaluable
for us. Their software capabilities, specifically in analytical
software, will help us to make progress in the area of virtual
microscopy, which is a field we have only recently stepped into. In
addition, Genetix’ experience and market leading products in cell
biology and genetics will expand our reach into the drug discovery
and development markets.”